Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients—rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial

Overview of attention for article published in Renal Replacement Therapy, April 2016

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial

Article in PLOS ONE (September 2022)

Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial

Article in Clinical Kidney Journal (August 2022)

Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial.

Article in JAMA (December 2018)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.